Abstract
The term “disease modifying drugs” (DMD) is taken from rheumatologists who coined it after the use of immunosuppressive drugs and, more recently, the association of “biological drugs” that changed the degenerative course of rheumatic disease.
In the treatment of multiple sclerosis (MS), the advent of interferon (IFN)-β, which caused a reduction in the number of relapses and possibly improvement in disability outcomes, was the first strategy to prevent inflammatory damage in the central nervous system (CNS). Soon after, glatiramer acetate showed similar results. It would be more than a decade before natalizumab was licensed, showing a much better efficiency in relapse reduction than was seen after first-line therapies failed. The pipeline is now much larger with several drugs on the horizon. Overall, the anti-inflammatory strategy has been mostly successful but drugs that have protection and repair mechanisms are still missing.
Keywords: Multiple sclerosis, treatments, mechanisms of action.
CNS & Neurological Disorders - Drug Targets
Title:Disease Modifying Drugs in Multiple Sclerosis: Mechanisms of Action and New Drugs in the Horizon
Volume: 11 Issue: 5
Author(s): Monica Marta and Gavin Giovannoni
Affiliation:
Keywords: Multiple sclerosis, treatments, mechanisms of action.
Abstract: The term “disease modifying drugs” (DMD) is taken from rheumatologists who coined it after the use of immunosuppressive drugs and, more recently, the association of “biological drugs” that changed the degenerative course of rheumatic disease.
In the treatment of multiple sclerosis (MS), the advent of interferon (IFN)-β, which caused a reduction in the number of relapses and possibly improvement in disability outcomes, was the first strategy to prevent inflammatory damage in the central nervous system (CNS). Soon after, glatiramer acetate showed similar results. It would be more than a decade before natalizumab was licensed, showing a much better efficiency in relapse reduction than was seen after first-line therapies failed. The pipeline is now much larger with several drugs on the horizon. Overall, the anti-inflammatory strategy has been mostly successful but drugs that have protection and repair mechanisms are still missing.
Export Options
About this article
Cite this article as:
Marta Monica and Giovannoni Gavin, Disease Modifying Drugs in Multiple Sclerosis: Mechanisms of Action and New Drugs in the Horizon, CNS & Neurological Disorders - Drug Targets 2012; 11 (5) . https://dx.doi.org/10.2174/187152712801661301
DOI https://dx.doi.org/10.2174/187152712801661301 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antiviral Herbs - Present and Future
Infectious Disorders - Drug Targets Radiosynthesis of 2-deoxy-2-[18F]fluorothymidine ([18F]FT), a Putative PET Agent for Imaging HSV-TK Expression
Current Radiopharmaceuticals Inflammation Theories in Psychotic Disorders: A Critical Review
Infectious Disorders - Drug Targets Understanding Effects of Psychological Stress on Physiology and Disease Through Human Stressome - An Integral Algorithm
Current Bioinformatics Role of Cannabinoids and Endocannabinoids in Cerebral Ischemia
Current Pharmaceutical Design Initiation of the Immune Response by Extracellular Hsp72: Chaperokine Activity of Hsp72
Current Immunology Reviews (Discontinued) Tackling COVID-19 Through Ayurveda: A Review on the Herbs of Recommended Indian Remedies
Current Traditional Medicine Antiviral Treatment of Cytomegalovirus Infection
Infectious Disorders - Drug Targets Subunit Protein Vaccines: Theoretical and Practical Considerations for HIV-1
Current Molecular Medicine β-Catenin/TCF-4 Signaling Regulates Susceptibility of Macrophages and Resistance of Monocytes to HIV-1 Productive Infection
Current HIV Research Antiidiotype-Derived Killer Peptides As New Potential Tools to Combat HIV-1 and AIDS-Related Opportunistic Pathogens
Anti-Infective Agents in Medicinal Chemistry Levamisole-Induced Leukoencephalopathy in Russia: Analysis of 30 Cases
Current Drug Safety Exploring the Role of Nerve Growth Factor in Multiple Sclerosis: Implications in Myelin Repair
CNS & Neurological Disorders - Drug Targets Heparan Sulphate Proteoglycans and Viral Vectors : Ally or Foe?
Current Gene Therapy The Role of Microglial Cell Subsets in Alzheimers Disease
Current Alzheimer Research Using Functional Neuroimaging to Investigate the Mechanisms of Action of Selective Serotonin Reuptake Inhibitors (SSRIs)
Current Pharmaceutical Design Computer-Based Comparison of Structural Features of Envelope Protein of Alkhurma Hemorrhagic Fever Virus with the Homologous Proteins of Two Closest Viruses
Protein & Peptide Letters Molecular and Biological Aspects of the Bovine Immunodeficiency Virus
Current HIV Research Could Hippocampal Neurogenesis be a Future Drug Target for Treating Temporal Lobe Epilepsy?
CNS & Neurological Disorders - Drug Targets Recent Advances on Immunosuppressive Drugs and Remyelination Enhancers for the Treatment of Multiple Sclerosis
Current Pharmaceutical Design